Bioactive Glass (Sol-gel) for Alveolar Bone Regeneration After Surgical Extraction
Launched by ALEXANDRIA UNIVERSITY · Jun 12, 2013
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Bioactive glass has long been known as a bone graft substitute capable of bone augmentation. The current proposal introduces a newly tailored bioactive glass scaffold with multi-scale porosity prepared using the sol-gel technique to regenerate bone in extraction sockets with the aim of preserving the alveolar ridge. This novel material has the potential to enhance angiogenesis and osteogenesis thereby preserving the overall height and width of the alveolar bone by regenerating new bone that closely mimics the adjacent healthy one. Thirty patients requiring myofunctional therapy including pr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must have good oral hygiene (confirmed by OHI-S)
- • Patients who had voluntarily agreed on signing an informed consent including the duration and all the steps of the trial
- • Patients who are indicated for the administration of the type of local anesthesia used in the trial
- • Patients who need myofunctional therapy including premolar extraction as part of two stage treatment (class II division I)
- • Patients indicated for premolar extraction as a normal step in the treatment plan not intentionally for the experiment.
- • Patients who had undergone x- rays on the premolar teeth showing root form and the shape of the socket prior to extraction
- Exclusion Criteria:
- • Patients with history of bleeding disorders which will hinder the normal healing process of the needed sockets for the trial
- • Patients with history of allergy to foreign bodies , i.e. susceptible to reactions from Bioglass
- • Patients with history of hypertension and diabetes , rendering them not indicated for administration of the recommended type of local anesthesia nor even for extraction
- • Patients having HCV , HBV , HIV or other infectious diseases to make sure of the safety of the research team and the participants from probable infection .
- • Mentally retarded patients who are not able to understand the steps of the trial Patients with systemic diseases or febrile illness making them unable to follow the appointments arranged
- • Patients who simultaneously participate in other research studies
- • Patients with traumatic surgical extraction
Trial Officials
Mona Marei, prof
Principal Investigator
Alexandria University
About Alexandria University
Alexandria University, a leading academic institution in Egypt, is dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise to conduct rigorous studies that address pressing health challenges. By fostering partnerships with healthcare professionals, industry leaders, and regulatory bodies, Alexandria University aims to contribute to the global body of medical knowledge and enhance the quality of patient care through evidence-based findings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alexandria, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials